The expression and clinical significance of mast cell immunoglobulin like receptor 1 in clear cell renal cell carcinoma

doi:10.3877/cma.j.issn.1674-3253.2025.04.015

Abstract

Abstract:

Objective

To analyze the expression and clinical significance of mast cell immunoglobulin like receptor 1 (MILR1) in clear cell renal cell carcinoma (ccRCC) using bioinformatics combined with clinical samples.

Methods

Multiple public databases were applied to analyze the expression of MILR1 and its role on patient prognosis and the immune microenvironment of ccRCC. Constructing a nomogram based on MILR1. The MILR1 protein expression was detected and its clinical significance using human ccRCC tissue microarray.

Results

The mRNA and protein expression of MILR1 were elevated in ccRCC, which indicates poor prognosis and serves as a risk factor. A nomogram based on MILR1 can accurately predict the prognosis of patients. High expression of MILR1 is associated with the inhibitory immune microenvironment of ccRCC.

Conclusion

High expression of MILR1 in ccRCC indicates poor prognosis in patients, which is associated with inhibitory immune microenvironment.

Key words: Mast cell immunoglobulin like receptor 1, Clear cell renal cell carcinoma, Clinical significance, Bioinformatics, Tumor microenvironment

Xinfeng Liu, Yulin Deng, Xiaode Liu, Daoxian Yan, Shuangsheng Shi, Decheng Huang, Yue Liu, Xuebin Liu, Peng Xu, Chuanjiang Dong. The expression and clinical significance of mast cell immunoglobulin like receptor 1 in clear cell renal cell carcinoma[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(04): 483-491.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.04.015

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I04/483

Figures/Tables 9

References 22

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA A Cancer J Clin, 2022, 72(1): 7-33. DOI: 10.3322/caac.21708.
[2]	Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial[J]. J Clin Oncol, 2017, 35(6): 591-597. DOI: 10.1200/JCO.2016.70.7398.
[3]	Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1103-1115. DOI: 10.1056/NEJMoa1816047.
[4]	Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1116-1127. DOI: 10.1056/NEJMoa1816714.
[5]	Saliby RM, Labaki C, Jammihal TR, et al. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes[J]. Cancer Cell, 2024, 42(5): 732-735. DOI: 10.1016/j.ccell.2024.03.002.
[6]	Bi K, He MX, Bakouny Z, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma[J]. Cancer Cell, 2025, 43(6): 1177-1179. DOI: 10.1016/j.ccell.2025.05.009.
[7]	Rosellini M, Marchetti A, Mollica V, et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma[J]. Nat Rev Urol, 2023, 20(3): 133-157. DOI: 10.1038/s41585-022-00676-0.
[8]	Yang S, Han Z, Tan Z, et al. Machine learning-based integration develops a stress response stated T cell (Tstr)-related score for predicting outcomes in clear cell renal cell carcinoma[J]. Int Immunopharmacol, 2024, 132: 112017. DOI: 10.1016/j.intimp.2024.112017.
[9]	López-Cade I, García-Barberán V, Cabañas Morafraile E, et al. Genomic mapping of copy number variations influencing immune response in breast cancer[J]. Front Oncol, 2022, 12: 975437. DOI: 10.3389/fonc.2022.975437.
[10]	Liu S, Li G, Yin X, et al. Comprehensive investigation of malignant epithelial cell-related genes in clear cell renal cell carcinoma: development of a prognostic signature and exploration of tumor microenvironment interactions[J]. J Transl Med, 2024, 22(1): 607. DOI: 10.1186/s12967-024-05426-x.
[11]	Fu L, Bao J, Li J, et al. Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma[J]. Front Immunol, 2022, 13: 1021935. DOI: 10.3389/fimmu.2022.1021935.
[12]	Li Y, Fan C, Hu Y, et al. Multi-cohort validation: a comprehensive exploration of prognostic marker in clear cell renal cell carcinoma[J]. Int Immunopharmacol, 2024, 135: 112300. DOI: 10.1016/j.intimp.2024.112300.
[13]	Weng KQ, Liu JY, Li H, et al. Identification of Treg-related prognostic molecular subtypes and individualized characteristics in clear cell renal cell carcinoma through single-cell transcriptomes and bulk RNA sequencing[J]. Int Immunopharmacol, 2024, 130: 111746. DOI: 10.1016/j.intimp.2024.111746.
[14]	陈爽, 杨娜, 黄禹栋, 等. 肾透明细胞癌患者血清miR-21及miR-27b与预后的关系[J]. 实用医学杂志, 2024, 40(3): 343-347. DOI:10.3969/j.issn.1006-5725.2024.03.011.
[15]	贾欢, 王晓磊, 李春阳. 罕见并发于肾脏透明细胞癌的抗Yo抗体阳性的副肿瘤性小脑变性一例及文献复习[J/OL]. 中华临床医师杂志(电子版), 2024, 18(11): 1070-1074. DOI: 10.3877/cma.j.issn.1674-0785.2024.11.015.
[16]	Zebley CC, Zehn D, Gottschalk S, et al. T cell dysfunction and therapeutic intervention in cancer[J]. Nat Immunol, 2024, 25(8): 1344-1354. DOI: 10.1038/s41590-024-01896-9.
[17]	Xiong D, Yu H, Sun ZJ. Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy[J]. Acta Pharm Sin B, 2024, 14(8): 3416-3431. DOI: 10.1016/j.apsb.2024.04.022.
[18]	Baessler A, Vignali DAA. T cell exhaustion[J]. Annu Rev Immunol, 2024, 42(1): 179-206. DOI: 10.1146/annurev-immunol-090222-110914.
[19]	de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors[J]. Cancer Cell, 2020, 38(3): 326-333. DOI: 10.1016/j.ccell.2020.07.004.
[20]	Cillo AR, Cardello C, Shan F, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8⁺ T cells to promote antitumor immunity[J]. Cell, 2024, 187(16): 4373-4388.e15. DOI: 10.1016/j.cell.2024.06.036.
[21]	Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis[J]. J Immunother, 2007, 30(8): 825-830. DOI: 10.1097/CJI.0b013e318156e47e.
[22]	Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813. DOI: 10.1056/NEJMoa1510665.

Please choose a citation manager

Content to export